Arrhythmias and Conduction DisturbancesRelation of Chronic Obstructive Pulmonary Disease to Atrial and Ventricular Arrhythmias
Section snippets
Methods
This study protocol was approved by the Mayo Clinic Institutional Review Board. We retrospectively identified and searched the medical records at our institution for all unique adult patients who underwent clinically indicated 24-hour ECG Holter monitoring between the years 2000 and 2009. From this cohort, we identified those patients who performed pulmonary function testing (PFT) in our laboratory (spirometry variables necessary for inclusion: FEV1 and FVC). Relevant demographic variables,
Results
We included 7,441 patients in this study (age 64 ± 16 years, 49% woman, 92% Caucasian) of whom 3,121 (41.9%) were diagnosed with COPD based on the PFT results. Characteristics of the study cohort stratified according to the presence and severity of COPD are listed in Table 1. The Holter monitoring results (listed in Table 2) revealed that patients with COPD experienced significantly greater number of atrial premature complex (APC) and ventricular premature complex (VPC); this difference
Discussion
The novel findings of this study were as follows: (1) COPD and its severity were independently associated with the occurrence of AF on a 24-hour Holter monitor, (2) COPD presence and severity were independently associated with NSVT as recorded by a 24-hour Holter monitor; and (3) COPD served as a univariate risk factor for SustVT, but this association did not remain independent in a multivariate analysis. These findings suggest that COPD poses an important and previously underappreciated risk
Disclosures
Dr. Scanlon has been an investigator for clinical trials sponsored by the National Heart Lung and Blood Institute, Bethesda, Maryland, Department of Energy, Atlanta, Georgia, Boehringer Ingelheim, Ridgefield, Connecticut, Dey L.P. Pharmaceutical, Napa, California, Forest, New York, New York, GlaxoSmithKline, Philadelphia, Pennsylvania, Novartis AG, Cambridge, Massachusetts, and Pfizer Inc., New York, New York. All other authors do not report any conflicts of interest.
References (30)
- et al.
Cardiovascular disease in COPD: mechanisms
Chest
(2013) - et al.
Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients
Ann Epidemiol
(2006) - et al.
Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease
Chest
(1988) - et al.
Longterm electrocardiographic monitoring of ambulatory patients with chronic airway obstruction
Chest
(1974) - et al.
Multifocal atrial tachycardia
Chest
(1998) - et al.
COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program
Chest
(2005) - et al.
Neurohumoral activation as a link to systemic manifestations of chronic lung disease
Chest
(2005) - et al.
Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial
J Am Coll Cardiol
(2010) - et al.
The role of Toll-like receptor 2 and hypoxia-induced transcription factor-1alpha in the atrial structural remodeling of non-valvular atrial fibrillation
Int J Cardiol
(2013) - et al.
Acute electrophysiologic effects of inhaled salbutamol in humans
Chest
(2005)
Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study
Chest
Interactions between COPD and outcomes after percutaneous coronary intervention
Chest
The state of US health, 1990–2010: burden of diseases, injuries, and risk factors
JAMA
Chronic obstructive pulmonary disease and the risk of cardiovascular diseases
Eur J Epidemiol
Cardiac arrhythmias in hospitalized patients with chronic obstructive pulmonary disease
Am Rev Respir Dis
Cited by (0)
This study was supported in part by European Regional Development Fund—Project FNUSA-ICRC CARDIO 3 and 5—No. CZ.1.05/1.1.00/02.0123.
See page 276 for disclosure information.